Synthetic CSF Matrices for Reliable Alpha-Synuclein Seed Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Seed Amplification Assays (SAAs) face challenges in using human cerebrospinal fluid (CSF) as a control solution due to its complexity and variability, which can induce self-aggregation or inhibit seeded aggregation, making it unreliable for diagnostic purposes.
Innovation Solution
Development of a synthetic CSF (sCSF) comprising human serum albumin (HSA) or other plasma proteins, along with an aqueous physiological salt solution, which serves as a stable and reproducible matrix for SAAs, allowing for accurate detection of misfolded protein aggregates without self-aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human cerebrospinal fluid (CSF) is used as a control solution in Seed Amplification Assays, then the assay can detect misfolded protein aggregates, but the complexity and variability of human CSF induces self-aggregation or inhibits seeded aggregation, making it unreliable
Solution Approach 1:
The patent creates a simplified copy of cerebrospinal fluid by using human serum albumin (HSA) as a surrogate for the complex CSF matrix. This HSA-based control solution replicates the essential functional properties of CSF while eliminating its variability and complexity, providing a reliable and reproducible control system for SAAs
Solution Approach 2:
The patent changes the fundamental parameters of the control solution by replacing human CSF with a defined composition of HSA at specific concentrations (0.1-10 mg/mL). This parameter change transforms the control solution from a complex, variable biological fluid to a standardized, reproducible protein solution with controlled properties
2Ease of manufacture
If human CSF is used as a control solution, then it can be obtained from donors, but its variability between donors and conditions makes it inconsistent for diagnostic purposes
Solution Approach 1:
The patent replaces the need for donated human CSF samples with a synthetic HSA-based control solution that can be manufactured indefinitely with consistent properties. This disposable-like approach using standardized HSA solutions eliminates donor variability while maintaining ease of preparation
Solution Approach 2:
The HSA-based control solution serves multiple functions: it works as both negative control (without seeds) and positive control (with synthetic seeds), replacing the need for different types of human CSF samples. This universal control solution can be used across different assays and laboratories with consistent results
3Measurement precision
If human CSF is used as a control solution, then it reflects the biological matrix, but it induces self-aggregation in negative controls or prevents aggregation in positive controls
Solution Approach 1:
The patent introduces HSA as an intermediary substance that mediates between the assay components and the control function. HSA provides the necessary protein matrix environment for accurate aggregation detection while simultaneously preventing unwanted self-aggregation in negative controls and not interfering with seeded aggregation in positive controls
Data Source
AI summary
Inert matrices for use with α-synuclein seed amplification assays (“αS-SAA” s) are provided. The inert matrices accurately reflect the absence of misfolded αS protein when used as a negative control, in the form of no, perceptively low, or delayed αS substrate self-aggregation, yet will readily permit aggregation of the αS substrate with seeds when used as a positive control. The inert matrices may be used to screen for αS-SAA reagent competence. The inert matrices may be used to dilute samples taken from peripheral biological matrices. Finally, the inert matrices may be used as a diluent for serial dilutions of αS-SAA samples, to enable semi-quantitative versions of αS-SAAs.